Status: Recruiting
A Phase 2 Study of CRD-4730 in CPVT
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Participants needed: 12
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Cardurion Pharmaceuticals, Inc.Updated: Feb 27, 2026Locations: 9
Eligibility criteria
The participant is male or female, ≥18 years of age and of legal adult age in ac... [+4]
The participant has clinically significant structural heart disease, diagnosis o... [+10]